NZ759327B2 - Aminothiazole compounds as protein kinase inhibitors - Google Patents

Abstract

Aminothiazole compounds of Formula (I) shown below and pharmaceutical compositions containing one of such compounds. Also disclosed are methods of inhibiting a tyrosine kinase and treating cancer associated with a tyrosine kinase with one of the aminothiazole compounds.

Description

(12) d patent specificaon (19) NZ (11) 759327 (13) B2 (47) Publicaon date: 2021.12.24 (54) AMINOTHIAZOLE NDS AS N KINASE INHIBITORS (51) Internaonal Patent Classificaon(s): A61K 31/4439A61K 31/496 A61K 31/506 C07D 417/14 A61P 35/00 (22) Filing date: (73) Owner(s): 2018.06.13 AL HEALTH RESEARCH INSTITUTES (23) Complete specificaon filing date: (74) Contact: 2018.06.13 Eagar & ates Pty Ltd (30) Internaonal Priority Data: (72) Inventor(s): US 62/518,855 2017.06.13 SHIH, Chuan JIAANG, Weir-Torn (86) Internaonal Applicaon No.: TSAI, Hui-Jen (87) Internaonal Publicaon number: WO/2018/231910 (57) Abstract: Aminothiazole compounds of Formula (I) shown below and pharmaceucal composions containing one of such compounds. Also disclosed are methods of inhibing a tyrosine kinase and treang cancer associated with a tyrosine kinase with one of the aminothiazole compounds.

NZ 759327 B2 AMINOTHIAZOLE NDS AS PROTEIN KINASE INHIBITORS BACKGROUND Protein s are important in cellular signal ys that regulate various cell functions, including differentiation, proliferation, migration, and apoptosis. Deregulation of protein kinases is implicated in cancer and a number of other diseases.

Tyrosine kinases, a subclass of protein kinases, te target protein function through transfer of phosphate from ATP to the hydroxyl group of a target protein tyrosine. FMS—like tyrosine kinase 3 (“FLT3”), vascular endothelial growth factor or (“VEGFR”), and tyrosine—protein kinase Kit (“c—Kit”) are three tyrosine kinases that have been studied as tive therapeutic targets in cancer treatment. ons of FLT3, a receptor tyrosine kinase, can lead to pment of cancer, e.g., acute myeloid leukemia. See Pratz et al., Current Drug Targets, 2010, 11(7), 781—9.

By binding to VEGFR and activating it via transphosphorylation, vascular endothelial growth factor, a signal protein, stimulates growth of new blood vessels. VEGFR has been identified as the predominant regulator of tumor angiogenesis. See Hicklin et al., J Clin Oncol., 2005, 23, 1011—1027. c—Kit, also a receptor tyrosine kinase, is involved in ellular signaling. The mutated form of c—Kit plays a crucial role in occurrence of some cancers. Inhibition of c—Kit has proved to be effective in treating gastrointestinal stromal tumor, acute myeloid leukemia, and melanoma.

See Babaei et al., Drug Des Devel Ther., 2016 10, 2443-2459.

Aminothiazoles compounds, extensively explored as potent tyrosine kinase inhibitors, t several challenges as drug candidates. They possess poor kinase selectivity, often cause animal death in toxicity studies, and generally lack adequate in viva exposure to exert desirable efficacy in pre—clinical or clinical s.

There is a need to develop new aminothiazole compounds that specifically inhibit certain tyrosine kinases, demonstrate desirable safety es, and exert sufficient in vivo efficacy in treating target cancers.

SUMMARY The present invention is based on unexpected discoveries that certain hiazole compounds effectively inhibit multiple tyrosine s, e.g., FLT3, VEGFR, and c—Kit.

In one aspect, this ion relates to aminothiazole compounds of Formula (I): (I), in which R1 is CH, alkyl or C1_6 kyl; X is O or NR3, in which Ra is H or C1_6 alkyl; Y is CRbRC or NRd, in which each of Rb and RC, ndently, is H, halo, C1_6 alkyl, C1_6 alkoxyl, or amino, or Rb, together with Ra, the carbon atom bonded to Rb, and the nitrogen atom bonded to Ra, is C340 heterocycloalkyl, and Rd is H or C1_6 alkyl, or Rd, together with R21 and the nitrogen atoms bonded to Rd and Ra, is €3-10 heterocycloalkyl; R2 is —CH2CH2Re or NRng, in which Re is H, halo, CH, alkyl, or OR}1 and each of Rf and R3, independently, is C1_6 alkyl or C3_g cycloalkyl, Rh being H or CH, alkyl, or Rh, together with Rd, the oxygen atom bonded to Rh, and the nitrogen atom bonded to Rd, being €3-10 heterocycloalkyl; and R3 is heteroaryl.

The term “alkyl” herein refers to a saturated, linear or branched hydrocarbon moiety, such as —CH3 or branched —C3H7. The term “cycloalkyl” refers to a non—aromatic, monocyclic, bicyclic, tricyclic, or tetracyclic hydrocarbon , such as cyclohexyl, cyclohexen-3—yl, or adamantyl. The term “alkoxyl” refers to an —O—alkyl radical. Examples of alkoxyl include, but are not limited to, methoxy, , n—propoxy, isopropoxy, n—butoxy, iso—butoxy, sec—butoxy, and tert—butoxy. The term “thioalkyl” refers to an —S—alkyl l. Examples of thioalkyl include, but are not limited to, methylthiol, hiol, and thiol. The te1m “heterocycloalkyl” refers to a non-aromatic, monocyclic, bicyclic, tricyclic, or tetracyclic moiety having one or more ring heteroatoms (e.g., N, O, or S). Examples of heterocycloalkyl include, but are not limited to, 4—morpholinyl, l—piperazinyl, 4—tetrahydropyranyl, and 4—pyranyl. The term “heteroaryl” refers to a moiety having one or more aromatic rings that contain at least one heteroatom (e.g., N, O, or S). Examples of heteroaryl moieties include furyl, furylene, fluorenyl, pyrrolyl, thienyl, oxazolyl, imidazolyl, thiazolyl, pyridyl, dinyl, quinazolinyl, quinolyl, isoquinolyl, and indolyl.

Alkyl, thioalkyl, alkoxyl, lkyl, heterocycloalkyl, and heteroaryl mentioned herein include both substituted and unsubstituted es, unless specified otherwise. Possible substituents on cycloalkyl, heterocycloalkyl, and heteroaryl include CHO alkyl, €2-10 alkenyl, C2- alkynyl, €3-20 lkyl, €3-20 lkenyl, €1-20 cycloalkyl, C1_20 heterocycloalkenyl, C140 alkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, amino, CHO mino, C140 dialkylamino, arylamino, diarylamino, hydroxyl, halogen, thio, €1-10 alkylthio, arylthio, €1-10 alkylsulfonyl, arylsulfonyl, acylamino, aminoacyl, aminothioacyl, amidino, guanidine, ureido, cyano, nitro, acyl, thioacyl, acyloxy, carboxyl, and carboxylic ester. On the other hand, possible substituents on alkyl e all of the above—recited substituents except €1-10 alkyl, €2-10 alkenyl, and €2-10 alkynyl. Cycloalkyl, heterocycloalkyl, aryl, and aryl can also be fused with each other.

The aminothiazole nds described above include the compounds themselves, as well as their salts, prodrugs, and solvates, if applicable. A salt, for example, can be formed between an anion and a positively charged group (e.g., amino) on an aminothiazole compound.

Suitable anions include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, acetate, malate, tosylate, tartrate, fumurate, glutamate, glucuronate, lactate, ate, and maleate. Likewise, a salt can also be formed between a cation and a negatively charged group (e.g., carboxylate) on an aminothiazole compound. Suitable cations e sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion. The aminothiazole compounds also include those salts containing quaternary nitrogen atoms. Examples of prodrugs include esters and other pharmaceutically acceptable derivatives, which, upon administering to a subject, are capable of providing active aminothiazole compounds. A e refers to a complex formed between an active aminothiazole compound and a pharmaceutically acceptable solvent. Examples of a pharmaceutically acceptable t include water, l, isopropanol, ethyl acetate, acetic acid, and ethanolamine.

In r aspect, this invention relates to a method for inhibiting a ne kinase, e.g., FLT3, VEGFR, and c—Kit. The method includes contacting the tyrosine kinase with an effective amount of one or more of the above-described aminothiazole compounds. 2018/037221 Also within the scope of this invention is a method for treating cancer associated with a tyrosine kinase. The method includes administering to a subject in need thereof an effective amount of one or more of the hiazole compounds of Formula (I) described above.

The tyrosine kinase associated to a cancer can be a wild type or mutant. Examples of the tyrosine kinase include, but are not limited to, FLT3, FLT4, VEGFR, platelet—derived growth factor receptor (PDGFR) A, PDGFR B, c—Kit, c—Src (SRC), tyrosine—protein kinase Lyn (LYN) A, LYN B, rearranged during transfection tyrosine kinase (RET), lymphocyte—specific protein tyrosine kinase, Gardner—Rasheed feline sarcoma viral oncogene homolog, din domain receptor 1, kinase insert domain receptor, B lymphocyte kinase, tyrosine—protein kinase Yes, Abelson murine leukemia viral oncogene homolog l (ABLl), tyrosine—protein kinase Tek, RET V804L, RET Y79lF, FLT3 D835Y, PDGFR A V56lD, or ABLl T3151.

In an exemplary method, the aminothiazole compounds of Formula (I) are used for treating cancer associated with FLT3, VEGFR, or c—Kit.

Examples of the cancer include acute myeloid leukemia, ma, c myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin’s disease, non— Hodgkin’s lymphoma, B—cell lymphoma, multiple myeloma, strom’s lobulinemia, ysplastic syndrome, pancreatic cancer, bladder cancer, ctal cancer, breast cancer, male genital tract cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, uterus cancer, gestational trophoblastic disease, gastric cancer, bile duct cancer, gallbladder cancer, small intestine cancer, esophageal cancer, oropharyngeal cancer, aryngeal cancer, eye , nerve cancer, head and neck cancer, melanoma, plasmacytoma, endocrine gland neoplasm, neuroendocrine cancer, brain tumor, bone cancer, and a (e.g., gastrointerstinal stromal tumor or GIST).

Further within the scope of this invention is a pharmaceutical composition containing one or more of the above—described aminothiazole compounds of Formula (I). The pharmaceutical composition can be used for treating cancer.

This invention also encompasses use of one or more of the above—described hiazole compounds of Formula (I) for the manufacture of a medicament for treating cancer.

The term “treating” or ment” refers to administering one or more of the aminothiazole compounds to a subject, who has an described disease, i.e., cancer, a symptom of such a disease, or a predisposition toward such a disease, with the e to confer a therapeutic effect, e. g., to cure, relieve, alter, affect, ameliorate, or t the above-described disease, the symptom of it, or the position toward it. “An effective amount” refers to the amount of an active compound that is required to confer the therapeutic effect. Effective doses will vary, as recognized by those skilled in the art, depending on the types of disease treated, route of administration, excipient usage, and the possibility of co—usage with other eutic treatment.

To practice the method of the present invention, a composition having one or more of the above—described hiazole compounds can be administered parenterally, orally, nasally, rectally, topically, or buccally. The term teral” as used herein refers to subcutaneous, intracutaneous, enous, intraperitoneal, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, hecal, intralesional, or ranial ion, as well as any suitable infusion technique.

A sterile able composition can be a solution or suspension in a non—toxic parenterally acceptable diluent or solvent, such as a solution in 1,3—butanediol. Among the acceptable vehicles and solvents that can be employed are mannitol, water, Ringer’s solution, and isotonic sodium chloride solution. In addition, fixed oils are tionally employed as a solvent or suspending medium (e.g., synthetic mono— or di—glycerides). Fatty acid, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically acceptable oils, such as olive oil and castor oil, ally in their polyoxyethylated versions. These oil solutions or suspensions can also contain a long chain alcohol diluent or dispersant, carboxymethyl cellulose, or similar sing agents. Other commonly used surfactants such as Tweens and Spans or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms can also be used for the purpose of formulation.

A composition for oral administration can be any orally acceptable dosage form including capsules, tablets, emulsions and aqueous suspensions, dispersions, and ons. In the case of tablets, ly used carriers include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions or emulsions are administered orally, the active ingredient can be suspended or dissolved in an oily phase combined with emulsifying or suspending agents. If d, certain sweetening, flavoring, or coloring agents can be added.

A nasal aerosol or inhalation composition can be prepared according to techniques well known in the art of pharmaceutical formulation. For example, such a composition can be prepared as a solution in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.

A composition having one or more of the above—described aminothiazole compounds can also be administered in the form of suppositories for rectal administration.

The carrier in the pharmaceutical composition must be “acceptable” in the sense that it is compatible with the active ingredient of the ition (and preferably, capable of stabilizing the active ingredient) and not deleterious to the subject to be treated. One or more solubilizing agents can be utilized as pharmaceutical ents for delivery of an active l,5—diphenyl—penta— 1,4—dien—3—one compound. Examples of other carriers include colloidal silicon oxide, magnesium stearate, cellulose, sodium lauryl sulfate, and D&C Yellow # 10.

The details of one or more embodiments of the invention are set forth in the ption below. Other features, s, and advantages of the invention will be nt from the description and from the claims.

DETAILED DESCRIPTION sed in detail are hiazole compounds of Formula (I): (I), in which variables R1, R2, R3, X, and Y are defined in the SUMMARY section above.

Typically, compounds of Formula (I) have R3 being 5— or 6—membered heteroaryl substituted with one or more Z moieties independently, in which n is 0 or 1 and Z is H, halo, CN, OH, CF3, CH, alkyl, or C1_6 alkoxyl; or have R3 being 5- or ered heteroaryl fused with a phenyl ring substituted with one or more substituents independently selected from the group consisting of H, halo, CN, OH, CF3, C1_6 alkyl, and C1_6 alkoxyl. Exemplary compounds have R3 being ered heteroaryl substituted with one or more (CH2)nZ moieties ndently, in which n is 0 or 1 and Z is H, halo, CN, OH, CF3, CH; alkyl, or C1_6 alkoxyl.

Two examples of R3 are pyridyl and pyrimidyl.

A group of the above—described novel aminothiazole compounds are nds of Formula (II): S’\<N£<X’\’++N \\ /N R3/K/ Y\R2 (H), in which R1 is C1_6 alkyl.

In one subset, nds of Formula (II) have X being O, Y being NRd, and R2 being — CHZCHzRe, in which Re is ORh, Rh, together with Rd, the oxygen atom bonded to Rh, and the en atom bonded to Rd, being C340 heterocycloalkyl. Compounds of this subset can have R3 being 5— or 6—membered heteroaryl substituted with one or more (CH2)nZ moieties independently, in which n is 0 or 1 and Z is H, halo, CN, OH, CF3, CH, alkyl, or CH, alkoxyl; or is 5— or 6—membered heteroaryl fused with a phenyl ring substituted with one or more substituents independently selected from H, halo, CN, OH, CF3, CH, alkyl, and CH, alkoxyl. For example, R3 can be pyridyl or pyrimidyl. Exemplary compounds include, but are not limited to, the ing compounds: 3V KM:H N O_\_ —\—Nfl \ \ \ \ O N\_/O | I N / and N/ In another subset, compounds of Formula (II) have X being NRa and Y being CRbRC or NRd, in which Ra, together with Rb, the nitrogen atom bonded to Ra, and the carbon atom bonded to Rb, is €3-10 heterocycloalkyl; RC is H, halo, C1_6 alkyl, C1_6 alkoxyl, or amino; and Rd, together with R21 and the nitrogen atoms bonded to R21 and Rd, is €3-10 heterocycloalkyl.

Of note, these nds can have X being NRa, Y being CRbRC, and R2 being NRng, in which Ra, together with Rb, the nitrogen atom bonded to Ra, and the carbon atom bonded to Rb, is C310 heterocycloalkyl; RC is H, halo, C1_6 alkyl, C1_6 alkoxyl, or amino; and each of Rf and Rg is C1_6 alkyl. They lly have R3 being 5— or 6—membered heteroaryl substituted with one or more (CH2)nZ moieties independently, in which n is O or 1 and Z is H, halo, CN, OH, CF3, CH, alkyl, or C1_6 alkoxyl; or is 5— or 6-membered heteroaryl fused with a phenyl ring substituted with one or more substituents independently selected from H, halo, CN, OH, CF3, C1_6 alkyl, and CH, alkoxyl. R3 can be pyridyl or pyrimidyl. ary compounds include, but are not limited to, the following compounds: N\ and / / On the other hand, the compounds in this subset can have X being NR3, Y being NRd, and R2 being —CH2CH2Re, in which Ra, er with Rd and the nitrogen atoms bonded to Ra and Rd, is €3-10 heterocycloalkyl; and Re is H, halo, or ORh, Rh being H or CH, alkyl. In general, these compounds have R3 being 5- or 6-membered heteroaryl substituted with one or more (CH2)nZ moieties ndently, in which n is O or 1 and Z is H, halo, CN, OH, CF3, CH, alkyl, or CH, alkoxyl; or is 5— or 6-membered heteroaryl fused with a phenyl ring substituted with one or more substituents independently selected from H, halo, CN, OH, CF3, C1_6 alkyl, and C1_6 alkoxyl. For instance, R3 is pyridyl or pyrimidyl. Exemplary compounds include, but are not limited to, the following compounds: N N \_ N \_\ _\ HN \ N / s\HNMN S \ N ON \N N \\~ \ 3 N\ | L N /N N l/ r group of the novel aminothiazole compounds set forth above are compounds of Formula (111): HNMN S:\<N X’\——Y\ (111), in which R1 is C1_6 alkyl.

An exemplary compound of formula (III) is 2018/037221 / \ \_ Listed below are exemplary compounds of this invention, each assigned a compound number.

N4 N4 N4 2NMN 2M 2NMN N O N\\ x N\ N/ 4 / 5 N_ N_ HN \ /N S \ SHN\/N\ N N I ON \\ O / N l/ N N \_ N 11 S/(NMNHN N \ ON / \ \_ Also within this invention is a pharmaceutical composition containing one or more of the aminothiazole compounds of Formula (I) for treating cancer.

Further covered by this invention is a method for treating cancer, the method including administering to a subject in need thereof an effective amount of a compound of a (1).

Synthetic chemistry transformations and protecting group methodologies (protection and de-protection) used for synthesizing the compounds of Formula (I) are well known in the art.

See, for example, R. , Comprehensive Organic Transformations (2m1 Ed., VCH Publishers 1999); P. G. M. Wuts and T. W. Greene, ’s Protective Groups in Organic Synthesis (4th Ed., John Wiley and Sons 2007); L. Fieser and M. Fieser, Fieser and Fieser’s Reagents for Organic Synthesis (John Wiley and Sons 1994); L. Paquette, ed., Encyclopedia of ts for c Synthesis (211d ed., John Wiley and Sons 2009); and G. J. Yu et al., J. Med. Chem. 2008, ], 6044-6054.

The compounds of Formula (I) thus prepared can be initially screened using biochemical assays, e. g., the kinase assays described in EXAMPLES 2—4 below, or cellular assays, e.g., the in vitro anticancer activity assay described in EXAMPLE 5 below, for their y in inhibiting tyrosine kinases or inhibiting the growth of cancer cells expressing certain tyrosine s.

They can be subsequently ted using in viva assays, e.g., a xenograft animal model assay, for their activity in suppressing tumor growth in a mammal. The selected compounds can be further tested to verify their efficacy in treating cancer. For e, a compound can be administered to an animal (e.g., a mouse) having cancer and its therapeutic effect is then assessed. Based on the results, appropriate dosage ranges and administration routes can be investigated and ined. t further elaboration, it is believed that one skilled in the art can, based on the above description, utilize the present invention to its fullest extent. The following specific examples are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. All publications cited herein are incorporated by reference in their entirety.

Shown in EXAMPLE 1 below are the synthesis and characterization of 13 exemplary compounds of Formula (I). The analytical data for the compounds thus prepared are also set forth in E 1 and the procedures for testing these nds are described in EXAMPLES 2—5 that .

All chemicals and ts were purchased from commercial suppliers and used as received. All reactions were carried out under an atmosphere of dry nitrogen. Reactions were monitored by TLC using Merck 60 F254 silica gel glass backed plates (5 X 10 cm); and zones were detected Visually under ultraviolet irradiation (254 nm) or by spraying with phosphomolybdic acid reagent (Aldrich) followed by heating at 80°C. All flash column chromatography was performed with Merck Kieselgel 60, No. 9385, 230—400 mesh ASTM silica gel as the stationary phase. Proton (1H) r magnetic resonance spectra were measured on a Varian Mercury—300 or Varian Mercury—400 spectrometer. Chemical shifts were recorded in parts per million (ppm) on the delta (8) scale relative to the resonance of the solvent peak. The following abbreviations were used to describe coupling: 3 = singlet; d = t; t = triplet; q = quartet; quin = quintet; br = broad; and m = multiplet. LCMS data were measured on an Agilent MSD—llOO ESI—MS/MS, Agilent 1200 series LC/MSD VL, and Waters Acquity UPLC—ESI— MS/MS system.

EXAMPLE 1: Synthesis of nds 1-13 Compounds 1-13 were prepared according to the synthetic route shown in Scheme 1 below. Among the listed reagents, TEA is ylamine, KOAc is ium acetate, Pd(PPh3)4 is tetrakis(triphenylphosphine)palladium(0), DMAc is N,N—dimethylacetamide, CsF is cesium fluoride, HCl is hydrochloric acid, NaHC03 is sodium bicarbonate, NaH is sodium hydride, NMP is 1—methyl—2—pyrrolidinone, KOH ium hydroxide, and DMSO is dimethyl ide.

O o E / a S > E / NR Py S PY b c, d S N o N) \E k N H PyCI' | N/>—H | N/>—NH2 A B N c D N \ \ py= I | / / N e N/ II/ \ N \ N I | N / / CIMCI LN W ' ”Hz \ R PyE />—NH / Py />—N RH N ' ' ' N H 2HC| R=2° amines or E N/ amine o. _ [N gfiynqm-i-grglazm-- R = 4-(2-hydroxyethyl)-morpholIne CIMCI 331235.219) Compounds 1- Scheme 1. Reagents and conditions: (a) TEA, CHzClz, 0 CC to rt; (b) KOAc, Pd(PPh3)4, DMAc, 150 OC (KOAc is replaced by CsF for Py= pyridinyl); (c) 12N HCl, H20, reflux; (d) NaHCO3, H20, rt; (e) NaH, NMP, 0 0C; (1) DMSO, RH, 100 0C or diglyme, KOH, 160 0C for RH = 4-(2-hydroxyethyl)-morpholine; and (g) 6N HCl, 0 OC.

Step 1. Synthesis 0f2,2-dimethyl-N—thiazol—2-yl-pr0pi0namide B To a mixture of 2—aminothiazole A (300 mmol) and triethylamine (330 mmol) in anhydrous CH2C12 (250 mL) at 0 °C was added trimethylacetyl chloride (310 mmol) and the mixture was stirred at room temperature under an argon atmosphere for 1 h. The mixture was washed with 6 N HCl (60 mL) and the organic layer was separated, dried over ium sulfate (MgSO4), and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (20% hexane) to give the titled product B as an ite solid (72%). 1H NMR (300 MHz, DMSO-d6): 5 11.75 (s, 1H), 7.46 (d, J = 6.0 Hz, 1H), 7.17 (d, J = 6.0 Hz, 1H), 1.22 (s, 9H); MS (ES+) m/z calcd. for OSI ; found: 185.1 (M+H+).

Step II. Synthesis of Compound C (Py= pyridin-3—yl, pyridinyl, and pyrimidin-S-yl) A mixture of 2,2—dimethyl-N—thiazol—2—yl—propionamide B (30 mmol), chloropyridine (30 mmol), potassium acetate (120 mmol) and tetrakis(triphenylphosphine)palladium(0) (1.5 mmol) in N,N—dimethylacetamide (60 mL) was heated at 150 0C under an argon atmosphere for 24 h. Most of solvent was removed by distillation (120 OC/160 mm Hg) and the residue was washed with water (250 mL). The precipitate was collected by filtration, redissolved in 10% CH2C12 (200 mL) and filtered through a pad of Celite. The filtrate was concentrated under reduced pressure and purified by chromatography on silica gel (1% HzClz) to give the desired product as an off—white solid (40-85%).

Step II. Synthesis of Compound C (Py= pyridin-Z-yl) A mixture of 2,2—dimethyl—N—thiazol—2—yl—propionamide B (10 mmol), chloropyridine (10 mmol), cesium fluoride (20 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.5 mmol) in dimethyl sulfoxide (20 mL) was heated at 160 °C under an argon here for 16 h. The resultant mixture was partitioned with 0.5N HCl (150 mL) and CH2C12 (150 mL). The organic layer was separated, dried over MgSO4, concentrated under reduced pressure and purified by tography on silica gel (3% acetone 2) to give the d product as a pale brown solid (20%) Only one of C was selected to show its NMR spectrum and Mass. | o \ s/%NJ\§ N H 2,2-Dimethyl-N-(5-pyridinyl-thiaz01yl)-pr0pi0namide. 1H NMR (400 MHz, CDC13)25 9.28 (bs, 1H), 8.61 (dd, J: 4.8, 1.6 Hz, 2H), 7.84 (s, 1H), 7.42 (dd, J: 4.8, 1.6 Hz, 2H), 1.38 (s, 9H); MS (ES+) m/z calcd. for C13H15N30S: 261.09; found: 262.1 (M+H+).

Step III. Synthesis of Compound D A mixture of C (5 mmol ) and 12 N HCl (5 mL) in water (5 mL) was heated to reflux for 2 h. Most of solvent was removed under reduced pressure and the residue was diluted with CH3OH (15 mL). Most of solvent was removed by distillation and the residue was dried in vacuo to give D hydrochloride as a pale brown solid.

To a stirred suspension of the above solid in water (30 mL) at room temperature was adjusted to pH = 7 with sodium bicarbonate and the e was stirred at 50 0C for 2 h. The itate was collected by filtration and dried in vacuo to give the desired product D as a pale brown solid (85—90%).

Only one of D was selected to show its NMR spectrum and Mass. \l S l /> NH2 -Pyridin-4—yl-thiazol-Z-ylamine. 1H NMR (300 MHz, DMSO—d6): 5 8.41 (dd, J = 4.8, 1.5 Hz, 2H), 7.73 (s, 1H), 7.48 (s, 2H), 7.35 (dd, J = 4.8, 1.5 Hz, 2H); MS (ES+) m/z calcd. for CgH7N3S: 177.04; found: 178.1 (M+H+).

Step IV. Synthesis of Compound E To a mixture of D or commercially ble 4—pyridin—3—yl—thiazol-2—ylamine (4 mmol) and 4,6—dichloro—2—methylpyrimidine (8 mmol) in 1—methyl—2—pyrrolidinone (20 mL) at 0 0C was added sodium hydride (60% in oil, 10 mmol) and the mixture was stirred at 0 0C under an argon atmosphere for 1 h. The reaction was quenched with water (100 mL) at 0 OC and was adjusted to pH = 2 with 6 N HCl. The slurry was adjusted to pH = 7 with sodium onate and the precipitate was collected by filtration, washed with water (50 mL) and dried in vacuo. The residue was purified by chromatography on silica gel (20% EtOAc/CHzClz, then 5% to 10% H2C12 gradient) to give the desired product E as a brown solid (45—60%).

Only one of E was selected to show its NMR spectrum and Mass.

N \ s MCI 1 %NH (6-Chloro-Z-methyl-pyrimidin-4—yl)-(5-pyridinyl-thiazol-Z-yl)-amine. 1H NMR (300 MHz, DMSO-d6): 5 12.15 (s, 1H), 8.53 (dd, J: 4.5, 1.5 Hz, 2H), 8.18 (s, 1H), 7.59 (dd, J: 4.5, 1.5 Hz, 2H), 6.90 (s, 1H), 2.59 (s, 3H); MS (ES+)n1/z calcd. for C13H10C1N5S: ; found: 304.1 (M+H+).

Step V. Synthesis of Compounds 1-4 and 7-13 A mixture of nd E (2 mmol) and l—ethylpiperazine (8 mmol) in dimethyl sulfoxide (2 mL) was heated at 100 0C for 1 h. After cooling to room temperature, the mixture was diluted with water (50 mL). The precipitate was collected by filtration, washed with water (10 mL) and dried in vacuo. The residue was purified by tography on aluminium oxide (0.5% to 1.5% MeOH/CHgClz gradient) to give freebase of each Compounds 1-4 and 7-13 as an off—white solid.

To a d 6 N HCl (10 mL) at 0 0C was added the above solid and the solution was filtered h a 0.45 um PVDF membrane. To the stirred filtrate was added e (40 mL) dropwise over the course of 1 h and was stirred for an additional 1 h at 0 0C. The precipitate was collected by filtration, washed with acetone (15 mL) and dried in vacuo to give the HCl salt of each Compounds 1-4 and 7-13 as a yellow solid (90—95%). [6—(4—Ethyl-piperazinyl)methyl-pyrimidinyl]-(5-pyridinyl-thiazolyl)- amine hydrochloride salt (Compound 1). 1H NMR (400 MHz, DMSO—d6): 5 11.55 (bs, 1H), 8.72 (d, J: 5.6 Hz, 2H), 8.61 (s, 1H), 8.14 (d, J: 5.2 Hz, 2H), 6.27 (s, 1H), 4.35 (d, J: 13.2 Hz, 2H), 3.55 (d, J = 12.0 Hz, 2H), 3.45 (t, J: 13.0 Hz, 2H), 3.13 (t, J: 5.8 Hz, 2H), 3.02 (q, J: .0 Hz, 2H), 2.50 (s, 3H), 1.28 (t, J: 6.8 Hz, 3H); MS (ES+) m/z calcd. for C19H23N7S: 381.17; found: 382.2 (M+H+). {6-[4-(2-Fluoro-ethyl)-piperazin-l-yl]methyl-pyrimidinyl}-(5-pyridinyl- thiazolyl)-amine hydrochloride salt (Compound 2). 1H NMR (300 MHz, DMSO—d6): 5 11.89 (bs, 1H), 8.73 (d, J = 6.3 Hz, 2H), 8.62 (s, 1H), 8.15 (d, J = 5.7 Hz, 2H), 6.26 (s, 1H), 4.95 (d, J = 47.4 Hz, 2H), 4.38 (s, 2H, overlapping with water peak), 3.70-3.35 (m, 6H), 3.18 (bs, 2H), 2.50 (s, 3H); MS (ES+) m/z calcd. for C19H22FN7S: 399.16; found: 400.1 . 2-{4-[2-Methyl(5-pyridinyl-thiazolylamino)-pyrimidinyl]-piperazin-l-yl}- ethanol hydrochloride salt und 3). 1H NMR (400 MHz, DMSO—d6): 8 11.03 (s, 1H), 8.73 (d, J: 7.2 Hz, 2H), 8.63 (s, 1H), 8.15 (d, J: 7.2 Hz, 2H), 6.26 (s, 1H), 4.34 (d, J = 12.4 Hz, 2H), 3.82 (t, J: 5.2 Hz, 2H), 3.62 (d, J = 12.0 Hz, 2H), 3.43 (t, J: 12.4 Hz, 2H), 3.30-3.09 (m, 4H), 2.49 (s, 3H); MS (ES+) m/z calcd. for C19H23N7OS: 397.17; found: 398.1 (M+H+). [6-(4-Dimethylamino-piperidinyl)methyl-pyrimidinyl]-(5-pyridinyl- thiazolyl)-amine hydrochloride salt (Compound 4). 1H NMR (300 MHz, DMSO—d6): 5 11.07 (s, 1H), 8.73 (d, J = 6.9 Hz, 2H), 8.62 (s, 1H), 8.15 (d, J: 6.9 Hz, 2H), 6.25 (s, 1H), 4.43 (d, J: 12.9 Hz, 2H), 3.44 (quin, J: 5.2 Hz, 1H), 2.94 (t, J: 12.5 Hz, 2H), 2.69 (d, J: 4.5 Hz, 6H), 2.49 (s, 3H), 2.15 (d, J: 10.5 Hz, 2H), 1.60 (q, J = 11.0 Hz, 2H); MS (ES+)n1/z calcd. for C20H25N7S: 395.19; found: 396.1 (M+H+). [6—(4—Ethyl-piperazinyl)methyl-pyrimidinyl]-(5-pyridinyl-thiazolyl)- amine hydrochloride salt (Compound 7). 1H NMR (400 MHz, DMSO—d6): 8 11.23 (bs, 1H), 9.15 (s, 1H), 8.68 (d, J: 5.2 Hz, 1H), 8.60 (d, J: 8.0 Hz, 1H), 8.19 (s, 1H), 7.93 (t, J: 6.2 Hz, 1H), 6.21 (s, 1H), 4.35 (d, J = 14.4 Hz, 2H), 3.55 (d, J = 11.6 Hz, 2H), 3.40 (t, J 213.2 Hz, 2H), 3.13 (t, J = 5.8 Hz, 2H), 3.01 (q, J = 6.9 Hz, 2H), 2.50 (s, 3H), 1.28 (t, J = 6.6 Hz, 3H); MS (ES+) m/z calcd. for C19H23N7S: 381.17; found: 382.2 (M+H+). {6-[4-(2-Fluoro-ethyl)-piperazin-l-yl]methyl-pyrimidinyl}-(5-pyridinyl- thiazolyl)-amine hydrochloride salt (Compound 8). 1H NMR (400 MHZ, DMSO-d6): 5 11.80 (bs, 1H), 9.16 (s, 1H), 8.68 (d, J = 5.6 Hz, 1H), 8.62 (d, J = 8.0 Hz, 1H), 8.20 (s, 1H), 7.95 (t, J: 6.8 Hz, 1H), 6.22 (s, 1H), 4.98 (d, J = 46.8 Hz, 2H), 4.34 (bs, 2H), 3.70—3.35 (m, 6H), 3.16 (bs, 2H), 2.49 (s, 3H); MS (ES+) m/z calcd. for FN7S: 399.16; found: 400.1 (M+H+). 2-{4—[2-Methyl(5-pyridinyl-thiazolylamino)-pyrimidinyl]-piperazinyl}- ethanol hydrochloride salt (Compound 9). 1H NMR (400 MHz, DMSO—d6): 5 11.02 (bs, 1H), 9.18 (s, 1H), 8.69 (s, 1H), 8.64 (d, J: 7.6 Hz, 1H), 8.22 (s, 1H), 7.96 (d, J = 5.2 Hz, 1H), 6.25 (s, 1H), 4.33 (d, J = 11.2 Hz, 2H), 3.80 (s, 1H), 3.60 (d, J: 11.6 Hz, 2H), 3.19 (s, 2H), 3.13 (s, 2H), 2.48 (s, 3H); MS (ES+) m/z calcd. for C19H23N7OS: 397.17; found: 398.1 (M+H+). [6-(4-Dimethylamino-piperidinyl)methyl-pyrimidinyl]-(5-pyridinyl- thiazolyl)-amine hydrochloride salt (Compound 10). 1H NMR (400 MHZ, DMSO—d6): 5 11.27 (bs, 1H), 9.18 (s, 1H), 8.69 (d, J = 5.2 Hz, 1H), 8.64 (d, J = 8.0 Hz, 1H), 8.23 (s, 1H), 7.97 (t, J: 6.8 Hz, 1H), 6.36 (bs, 1H), 4.42 (d, J = 8.8 Hz, 2H), 3.43 (bs, 1H), 2.99 (t, J: 12.4 Hz, 2H), 2.68 (s, 3H), 2.67 (s, 3H), 2.55 (s, 3H), 2.17 (d, J: 10.8 Hz, 2H), 1.64 (q, J: 9.2 Hz, 2H); MS (ES+) m/z calcd. for C20H25N7S: 395.19; found: 396.2 . [6—(4—Ethyl-piperazinyl)methyl-pyrimidinyl]-(5-pyridinyl-thiazolyl)- amine hydrochloride salt (Compound 11). 1H NMR (300 MHz, DMSO—d6): 5 11.34 (s, 1H), 8.54 (d, J: 4.8 Hz, 1H), 8.32 (s, 1H), .96 (m, 2H), 7.40—7.34 (m, 1H), 6.31 (s, 1H), 4.37 (d, J = 13.2 Hz, 2H), 3.62—3.38 (m, 4H), .90 (m, 4H), 2.47 (s, 3H), 1.26 (t, J = 7.4 Hz, 3H); MS (ES+) m/z calcd. for C19H23N7S: 381.17; found: 382.2 (M+H+). [6—(4—Ethyl-piperazinyl)methyl-pyrimidinyl]-(5-pyrimidin-S-yl-thiazolyl)- amine hydrochloride salt (Compound 12). 1H NMR (400 MHz, DMSO—d6): 5 11.35 (bs, 1H), 9.20-9.03 (m, 3H), 8.09 (s, 1H), 6.28 (s, 1H), 4.40 (s, 2H), 3.56 (d, J = 12.4 Hz, 2H), 3.44 (d, J: 7.4 Hz, 2H), 3.13 (bs, 2H), 3.02 (d, J: 8.0 Hz, 2H), 1.28 (bs, 3H); MS (ES+) m/z calcd. for ClgszNgSI 382.17; found: 383.3 (M+H+). [6-(4—Ethyl-piperazinyl)methyl-pyrimidinyl]-(4-pyridinyl-thiazolyl)- amine hydrochloride salt (Compound 13). 1H NMR (400 MHz, DMSO—d6): 8 11.80 (bs, 1H), 11.54 (bs, 1H), 9.28 (s, 1H), 8.94 (d, J = 8.4 Hz, 1H), 8.84 (d, J = 5.2 Hz, 1H), 8.15—8.07 (m, 2H), 6.31 (bs, 2H), 4.35 (d, J: 14.0 Hz, 2H), 3.55 (d, J = 12.0 Hz, 2H), 3.45 (t, J = 13.0 Hz, 2H), 3.15-3.07 (m, 2H), 3.00 (q, J = 10.0 Hz, 2H), 2.49 (s, 3H), 1.27 (t, J = 7.4 Hz, 3H); MS (ES+) m/z calcd. for C19H23N7S: 381.17; found: 382.1 (M+H+).

Step V. Synthesis of Compounds 5 and 6 To a mixture of Compound E (1 mmol) and ydroxyethy1)—morpholine (4 mmol) in diglyme (1 mL) at 100 0C was added potassium hydroxide (10 mmol) and the mixture was stirred at 160 0C under an argon atmosphere for 10 min. The reaction was quenched with water (20 mL) at 0 OC and was adjusted to pH = 2 with 6 N HCl. The slurry was adjusted to pH = 7 with sodium bicarbonate and the precipitate was collected by tion, washed with water (10 mL) and dried in vacuo. The residue was purified by chromatography on aluminium oxide (0.5% to 1.5% MeOH/CH2C12 gradient) to give freebase of Compound 6 as an off—white solid.

To a suspension of the above solid in MeOH (10 mL) at 0 0C was added 6 N HCl (1 mL) with stirring. Most of solvent was removed under reduced pressure and the residue was treated with EtOH (10 mL). The itate was collected by filtration, washed with acetone (10 mL) and dried in vacuo to give the HCl salt of each compounds 5-6 as a yellow solid (45—50%). [2-Methyl(2-morpholinyl-ethoxy)-pyrimidinyl]-(5-pyridinyl-thiazolyl)- amine hydrochloride salt (Compound 5). 1H NMR (400 MHz, DMSO—d6): 5 11.61 (s, 1H), 8.74 (d, J: 5.2 Hz, 2H), 8.64 (s, 1H), 8.17 (d, J: 5.2 Hz, 2H), 6.37 (s, 1H), 4.72 (s, 2H), 4.00- 3.80 (m, 4H), 3.64—3.42 (m, 4H), 3.16 (bs, 2H), 2.59 (s, 3H); MS (ES+) m/z calcd. for N6OZS: 398.15; found: 399.2 (M+H+). [2-Methyl(2-morpholinyl-ethoxy)-pyrimidinyl]-(5-pyridinyl-thiazolyl)- amine hydrochloride salt (Compound 6). 1H NMR (400 MHz, DMSO—d6): 5 11.51 (bs, 1H), 9.20 (s, 1H), 8.71 (d, J = 5.6 Hz, 1H), 8.66 (d, J: 8.4 Hz, 1H), 8.24 (s, 1H), 7.98 (dd, J = 8.0, .6 Hz, 1H), 6.35 (s, 1H), 4.72 (t, J = 4.8 Hz, 2H), 3.96 (d, J = 10.8 Hz, 2H), 3.85 (t, J = 12.0 Hz, 2H), 3.55 (bs, 2H), 3.47 (d, J = 12.4 Hz, 2H), 3.19 (bs, 2H), 2.59 (s, 3H); MS (ES+) m/z calcd. for N602S: 398.15; found: 399.1 (M+H+).

EXAMPLE 2: Inhibiting FLT3 activity A study was carried out as s to test certain compounds prepared according to EXAMPLE 1 in inhibiting FLT3 ty.

GST-FLT3—KDWT containing the FLT3 kinase catalytic domain (residues Y567—S993) was sed in Sf9 insect cells transfected the baculovirus containing pBac—PAKS—GST—FLT3— KD plasmid. An FLT3WT Kinase—Glo assay was carried out in l plates at 30 °C for 4 hrs to test compound in a final volume of 50 ul including the following components: 75 ng GST- FLT3-KDWT proteins, 25 mM HEPES, pH 7.4, 4 mM MnClz, 10 mM MgC12, 2 mM DTT, 0.02% Triton X—100, 0.1 mg/ml bovine serum n, 25 uM Her2 peptide ate, 0.5 mM , and 1 uM ATP. ing incubation, 50 Ml Kinase—Glo Plus Reagent (Promega, Madison, WI, USA) was added to each well and the mixture was incubated at 25 °C for 20 min. A 70—uL aliquot of each reaction mixture was transferred to a black microtiter plate and the luminescence was measured on Wallac Vector 1420 multilabel counter (PerkinElmer, Shelton, CT, USA).

Multiple compounds were tested. Unexpectedly, Compounds 1-33 showed IC50 (the concentration of an inhibitor where the response is reduced by half) values lower than 100 nM.

EXAMPLE 3: Inhibiting VEGFR2 activity A study was carried out as follows to test certain compounds prepared according to EXAMPLE 1 in inhibiting VEGFR2 activity. Note that VEGFR2 is one of the three main subtypes of VEGFR.

The recombinant GST—VEGFR2 (residues V789—V1356) containing kinase domain was expressed in Sf9 insect cells. The kinase assay was d out in 96—well plates with tested compound in a final volume of 50 pl reaction at 30°C for 120 s with following ents: 25 mM HEPES pH 7.4, 10 mM MgC12, 4 mM MnClz, 0.5 mM Na3VO4, 2 mM DTT, 0.02% Triton X100, 0.01% BSA, 1 HM ATP, 2 uM polyGlu4zTyr peptide, 50~100 ng recombinant VEGFR2. Following incubation, 50 Ml Kinase—Glo Plus Reagent (Promega, Madison, WI, USA) was added to each well and the mixture was incubated at 25 °C for 20 min.

A 70—ML aliquot of each reaction mixture was transferred to a black microtiter plate and the luminescence was measured on Wallac Vector 1420 multilabel counter (PerkinElmer, Shelton, CT, USA). le compounds were tested in the VEGFR2 assay. nds 1, 9 and 10 unexpectedly showed IC50 values lower than 30 nM.

EXAMPLE 4: ting c—Kit activity A study was carried out as follows to test certain compounds prepared ing to EXAMPLE 1 in inhibiting c—Kit activity.

The inal His-tagged human c-KIT (residues T544-V976) recombinant proteins, sed in Sf9 baculovirus—insect cell expression systems, were purified for c—KIT ADP Kinase—Glo assay. A c—Kit—ADP Kinase—Glo assay was carried out in 96—well plates at 30 °C for 150 mins with a final volume of 10 ul, including 40 mM Tris pH 7.4, 20 mM MgC12, 2 mM MnClz, 2 mM DTT, 0.01% BSA, 20 uM ATP, 20 uM poly(Glu,Tyr) 4:1 peptide, 0.1 mM Na3VO4, 250 ng of recombinant c-Kit proteins, and a tested compound at the indicated concentration. The reactions were stopped by the addition of 5 ul ADP—GloTM t (Promega, Madison, WI, USA) at 25 °C with 40 min incubation, followed by 10 ul of kinase detection reagent for a further 30 min. Finally, a 30 ul aliquot of each reaction mixture was transferred to a black microtiter plate and the luminescence was measured on Wallac Vector 1420 multilabel counter (Perkin-Elmer, Shelton, CT, USA).

Multiple compounds were tested. Unexpectedly, Compounds 1-7 and 11-12 showed IC50 values lower than 100 nM.

EXAMPLE 5: In vitro anticancer activity A study was carried out as follows to evaluate in vitro anticancer activity of certain nds ed according to EXAMPLE 1 using cell lines and MTS cell Viability assays (MTS represents 3—(4,5—dimethylthiazol—2-yl)—5—(3-carboxymethoxyphenyl)—2-(4—sulfophenyl)- 2H—tetrazolium).

Leukemia cell lines MOLM—13, MV4:11, and Kasumin-l were sed from American Type Culture Collection (ATCC, Manassas, VA, USA). The human gastrointestinal stromal tumor GIST-T1 cell line was purchased from Cosmo Bio Co., LTD (Tokyo, Japan). All leukemia cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 10 U/ml penicillin, and 10 g/ml streptomycin at 37°C and 5% C02. The cell line 1 was cultured in DMEM medium supplemented with 10% FBS, 0.01% nonessential amino acids, 10 U/ml penicillin, and 10 g/ml streptomycin.

GIST882, GIST48 and GIST430 cells were all cultured in incubators maintained at 37 °C and 5% C02. GIST882 was cultured in RPMI—1640 mented with 20% fetal bovine serum (FBS). GIST48 was cultured with F10 supplemented with 20% FBS, 0.5% Mito, serum extender (BD Bioscience, 355006) and 1% pituitary extract bovine (BD Bioscience 354123). 0 was cultured in IMDM supplemented with 20% FBS. GIST882, GIST430 and GIST48 cells were provided by Dr. Jonathan A. Fletcher (Harvard l School, US).

MOLM—I3, MV4:]1, and Kasumin-I MTS assays Cells were seeded in 96-well culture plates at a density of 1><104 cells/100 ul/well in triplicates and were treated for 72 hours with an indicated concentration of test compound ranging from 1 nM to 10 uM. Colorimetric CellTiter 96® Aqueous One Solution Cell Proliferation assay (MTS assay; Promega, n, WI, USA) was used to determine the cytotoxicity. The l density at 492 nm was measured using a late photometer (Victor2; Perkin-Elmer, m, MA, USA). IC50 values were determined by MTS assay when cells were treated with test compound for 72 hours and calculated with GraphPad Prism 6. Each experiment was in triplicate.

GIST—T] MTS assay GIST—T1 cells were seeded in l culture plates at a density of 8000 cells/100 l in triplicates and were treated for 72 hours with an indicated concentration of test compound ranging from 1 nM to 10 uM. Colorimetric CellTiter 96® Aqueous One Solution Cell Proliferation assay (MTS assay; Promega, n, WI, USA) was used to determine the cytotoxicity. The optical density at 492 nm was measured using a microplate photometer (Victor2; —Elmer, Waltham, MA, USA). IC50 values were determined by MTS assay when cells were treated with test compound for 72 hours and calculated with GraphPad Prism 6. Each experiment was in triplicate.

GIST882, GIST48, and GIST430 MTS assays GIST cells (4 X 104) were treated with different dosage of compounds. The treated GIST882 cells were incubated for 144 hours and GIST48 and GIST430 cells were incubated for 120 hours at 37°C in 5% C02. Cell proliferation was determined by incubating the cells with methylene blue ech, CA, US) for 1 hour. The ance was measured at 450 nm using SpectraMax M5 microplate reader (Molecular Devices, US).

The GI50 (the concentration for 50% of maximal inhibition of cell eration) values of certain compounds of Formula (I) are shown in the table below: GI50 (nM) Compound MOLM-13 MV4:11 Kasumi-1 GIST-T1 GIST430 GIST48 GIST882 1 10 13 11 11 3.8 19 5.0 7 62 34 266 53 60 820 20 12 211 132 349 119 ND ND ND ND, not determined.

OTHER EMBODIMENTS All of the features disclosed in this specification may be combined in any combination.

Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.

From the above description, one d in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are also within the scope of the following claims.

Throughout this ication, unless otherwise ted, "comprise," "comprises," and "comprising," (and variants thereof) or related terms such as "includes" (and variants thereof), are used inclusively rather than exclusively, so that a stated integer or group of integers may include one or more other non-stated integers or groups of integers.

Throughout this ication, nce to any advantages, promises, objects or the like should not be regarded as cumulative, composite, and/or tive, and should be regarded as preferable or desirable rather than stated as a warranty.

Claims (27)

CLAIMS :

1. A compound of formula (I) below or a pharmaceutically acceptable salt thereof: (I), wherein R1 is C1-6 alkyl or C1-6 kyl; X is O or NRa, in which Ra is H or C1-6 alkyl; Y is CRbRc or NRd, in which each of Rb and Rc, independently, is H, halo, C1-6 alkyl, C1-6 alkoxyl, or amino, or Rb, together with Ra, the carbon atom bonded to Rb, and the nitrogen atom bonded to Ra, is C3-10 heterocycloalkyl; and Rd is H or C1-6 alkyl, or Rd, together with Ra and the nitrogen atoms bonded to Rd and Ra, is C3-10 heterocycloalkyl; R2 is –CH2CH2Re or NRfRg, in which Re is H, halo, C1-6 alkyl, or ORh and each of Rf and Rg, independently, is C1-6 alkyl or C3-8 cycloalkyl, Rh being H or C1-6 alkyl, or Rh, together with Rd, the oxygen atom bonded to Rh, and the nitrogen atom bonded to Rd, being C3-10 cycloalkyl; and R3 is 6-membered heteroaryl.

2. The compound or salt of claim 1, wherein the compound is of formula (II): (II), in which R1 is C1-6 alkyl.

3. The compound or salt of claim 2, wherein X is O, Y is NRd, and R2 is – Re, in which Re is ORh, Rh, er with Rd, the oxygen atom bonded to Rh, and the nitrogen atom bonded to Rd, being C3-10 heterocycloalkyl.

4. The compound or salt of claim 2, wherein X is NRa and Y is CRbRc or NRd, in which Ra, together with Rb, the nitrogen atom bonded to Ra, and the carbon atom bonded to Rb, is C3-10 heterocycloalkyl; Rc is H, halo, C1-6 alkyl, C1-6 alkoxyl, or amino; and Rd, together with Ra and the nitrogen atoms bonded to Ra and Rd, is C3-10 heterocycloalkyl.

5. The compound or salt of claim 4, wherein X is NRa, Y is CRbRc, and R2 is NRfRg, in which Ra, together with Rb, the nitrogen atom bonded to Ra, and the carbon atom bonded to Rb, is C3-10 heterocycloalkyl; Rc is H, halo, C1-6 alkyl, C1-6 alkoxyl, or amino; and each of Rf and Rg is C1-6 alkyl.

6. The compound or salt of claim 4, wherein X is NRa, Y is NRd, and R2 is – CH2CH2Re, in which Ra, together with Rd and the nitrogen atoms bonded to Ra and Rd, is C3-10 heterocycloalkyl; and Re is H, halo, or ORh, Rh being H or C1-6 alkyl.

7. The compound or salt of claim 1, wherein R3 is 6-membered heteroaryl substituted with one or more (CH2)nZ moieties independently, in which n is 0 or 1 and Z is H, halo, CN, OH, CF3, C1-6 alkyl, or C1-6 alkoxyl; or is 6-membered heteroaryl fused with a phenyl ring substituted with one or more substituents independently ed from the group consisting of H, halo, CN, OH, CF3, C1-6 alkyl, and C1-6 l.

8. The compound or salt of claim 7, wherein R3 is 6-membered heteroaryl substituted with one or more (CH2)nZ moieties independently, in which n is 0 or 1 and Z is H, halo, CN, OH, CF3, C1-6 alkyl, or C1-6 alkoxyl.

9. The nd or salt of claim 8, wherein R3 is pyridyl or pyrimidyl.

10. The compound or salt of claim 3, n R3 is 6-membered heteroaryl substituted with one or more (CH2)nZ moieties independently, in which n is 0 or 1 and Z is H, halo, CN, OH, CF3, C1-6 alkyl, or C1-6 alkoxyl; or is 6-membered heteroaryl fused with a phenyl ring substituted with one or more substituents independently selected from the group ting of H, halo, CN, OH, CF3, C1-6 alkyl, and C1-6 alkoxyl.

11. The compound or salt of claim 10, wherein R3 is pyridyl or pyrimidyl.

12. The compound or salt of claim 11, wherein the compound is

13. The compound or salt of claim 5, wherein R3 is 6-membered heteroaryl substituted with one or more (CH2)nZ moieties independently, in which n is 0 or 1 and Z is H, halo, CN, OH, CF3, C1-6 alkyl, or C1-6 alkoxyl; or is 6-membered aryl fused with a phenyl ring substituted with one or more substituents independently selected from the group consisting of H, halo, CN, OH, CF3, C1-6 alkyl, and C1-6 alkoxyl.

14. The compound or salt of claim 13, wherein R3 is pyridyl or pyrimidyl.

15. The compound or salt of claim 14, wherein the compound is

16. The compound or salt of claim 6, wherein R3 is 6-membered heteroaryl substituted with one or more (CH2)nZ moieties independently, in which n is 0 or 1 and Z is H, halo, CN, OH, CF3, C1-6 alkyl, or C1-6 alkoxyl; or is 6-membered heteroaryl fused with a phenyl ring substituted with one or more substituents independently selected from the group ting of H, halo, CN, OH, CF3, C1-6 alkyl, and C1-6 alkoxyl.

17. The compound or salt of claim 16, wherein R3 is pyridyl or pyrimidyl.

18. The nd or salt of claim 17, wherein the compound is one of the following compounds:

19. The compound or salt of claim 1, wherein the compound is one of the ing compounds:

20. The compound or salt of claim 1, n the compound is of formula (III): (III), in which R1 is C1-6 alkyl.

21. A pharmaceutical composition comprising a pharmaceutically acceptable r and a nd or salt according to any one of claims 1 to 20.

22. Use of a compound or salt according to any one of claims 1 to 20, or a pharmaceutical composition according to claim 21, in the manufacture of a medicament for treating a cancer associated with a ne kinase.

23. A compound or salt according to any one of claims 1 to 20 or a pharmaceutical composition according to claim 21 for use in inhibiting a tyrosine kinase.

24. A nd or salt according to any one of claims 1 to 20 or a ceutical composition according to claim 21 for use in the treatment of a cancer associated with a tyrosine kinase.

25. The use of claim 22, or the nd of claim 23 or claim 24, wherein the tyrosine kinase is FMS-like tyrosine kinase 3 (FLT3), FMS-like tyrosine kinase 4, vascular endothelial growth factor receptor (VEGFR), colony stimulating factor 1 receptor (CSF1R), platelet-derived growth factor receptor (PDGFR) A, PDGFR B, tyrosine-protein kinase Kit (c-KIT), c-Src (SRC), tyrosine-protein kinase Lyn (LYN) A, LYN B, rearranged during transfection tyrosine kinase (RET), lymphocyte-specific protein tyrosine kinase, Gardner-Rasheed feline sarcoma viral oncogene homolog, discoidin domain receptor 1, kinase insert domain receptor, B lymphocyte , tyrosine-protein kinase Yes, Abelson murine leukemia viral oncogene homolog 1 , tyrosine receptor kinase TRKA, TRKB, TRKC, ZAK/MLTK, IRAK4, RET V804L, RET Y791F, FLT3 D835Y, PDGFR A V561D, or ABL1 T315I.

26. The use of claim 25, or the compound of claim 25, wherein the tyrosine kinase is FLT3, VEGFR, or c-KIT.

27. The use according to any one of claims 22, 25, or 26, or the compound according to any one of claims 23 to 26, wherein the cancer is acute myeloid leukemia, chloroma, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin’s disease, non-Hodgkin’s ma, B-cell lymphoma, multiple myeloma, Waldenstrom’s macroglobulinemia, myelodysplastic syndrome, pancreatic cancer, bladder cancer, colorectal cancer, breast , male genital tract cancer, renal cancer, hepatocellular cancer, lung , ovarian cancer, cervical cancer, uterus cancer, gestational trophoblastic disease, gastric cancer, bile duct cancer, gallbladder cancer, small intestine cancer, geal cancer, oropharyngeal cancer, hypopharyngeal cancer, eye cancer, nerve cancer, head and neck cancer, melanoma, plasmacytoma, endocrine gland neoplasm, ndocrine cancer, brain tumor, bone cancer, or sarcoma.